AX-2026-043497 · GHRP-6 · QST lot QST-2508-M5445

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	98.42	% area	≥ 99.0	FAIL
Total impurities	RP-HPLC, sum of reported peaks	1.58	% area	≤ 1.0	FAIL
Largest single impurity	RP-HPLC — des-Lys (−128 Da)	1.11	% area	≤ 1.00	FAIL
Identity — theoretical monoisotopic mass	calculated from molecular formula	872.4446	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	872.4463	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+2.0	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	88.98	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	87.57	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	2.22	mg	2 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	1.944	mg	2 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	97.2	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	5.82	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.77	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.43	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.83	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	8.33	min	8.44 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.86	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	37,629	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Trp]-epimer	0.68	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 37,629, and skew follows the reported asymmetry factor of 0.86. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 1.11 % impurity against a 98.42 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	GHRP-6 — main peak	8.33	4,783,517	98.42	—
2	des-Lys (−128 Da)	8.11	53,949	1.11	-128.095
3	[D-Trp]-epimer	8.21	15,067	0.31	0.000
4	oxidised Trp (+16 Da)	7.99	4,860	0.10	+15.995
5	bis-oxidised Trp (+32 Da)	7.75	2,916	0.06	+31.990
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 872.4446 Da, computed from C46H56N12O6. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 872.4463 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	437.2296	437.2304	0.0008	51.4
1+	873.4519	873.4536	0.0017	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	5.82
Counter-ion (acetate)	ion chromatography	4.77
Residual solvent + inorganic residue	estimated	0.43
Total peptide content	by difference	88.98
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.37	98.42	divergence -0.05 pp vs batch median
Total impurities (% area)	1.63	1.58
Largest single impurity (% area)	0.82	1.11
Water (%)	not stated	5.82
Counter-ion (%)	not stated	4.77
Peptide content (%w/w)	not stated	88.98
Endotoxin (EU/mg)	0.27	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Domestic warehouse despatch → submitter (2–8 °C, 16 d) → laboratory (courier, cold pack, 9 d) → assay.
Assay date: 22 Jan 2026
Submitted to the index: 04 Feb 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

wide_iqr04 Feb 2026

The actionable statistic for a buyer is not the median but the tenth percentile — how bad a bad lot is. This record is a data point for that percentile and it is worth more to the index than another result at the top.

deamidation_rate04 Feb 2026

Deamidation is time, temperature and sequence. If the deamidated species is prominent here, the manufacture date on lot QST-2508-M5445 against the assay date above is the first arithmetic to do.

ms_confirm04 Feb 2026

A reference standard on the same sequence would upgrade this from a good mass to a traceable one. The distinction matters where a result is going to be cited rather than merely read.

Section 7

Related records

Same batch — lot QST-2508-M5445 n=1

This is the only report on this lot. One report is not a batch characterisation.

Batch rollup and reproducibility assessment →

Cross-sections

Other recent GHRP-6 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042012	AMB	AMB-2603-S5667	Janoshik	2026-Q3	99.37	5.90	88.8	Laboratory-retained	1	MARGINAL
AX-2026-042528	HJ	HJ-2603-R5329	VendorInvestigate	2026-Q3	98.69	1.87	95.8	Buyer-sourced	0	FAIL
AX-2026-042015	AMB	AMB-2603-S5667	Janoshik	2026-Q3	99.54	6.44	97.1	Buyer-sourced	0	PASS
AX-2026-042526	HJ	HJ-2603-R5329	Medutest	2026-Q3	99.37	3.06	—	Laboratory-retained	0	PASS
AX-2026-042527	HJ	HJ-2603-R5329	VendorInvestigate	2026-Q3	99.21	2.77	93.2	Buyer-sourced	0	PASS
AX-2026-042525	HJ	HJ-2603-R5329	Janoshik	2026-Q3	99.52	3.24	92.0	Buyer-sourced	0	PASS
AX-2026-042013	AMB	AMB-2603-S5667	Kestrel	2026-Q3	99.93	5.75	—	Buyer-sourced	0	PASS
AX-2026-042017	AMB	AMB-2603-S5667	Medutest	2026-Q3	99.76	6.42	97.4	Buyer-sourced	0	PASS

Other recent QST records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043498	MOTS-c	QST-2511-H5351	Kestrel	2026-Q2	98.36	5.08	—	Buyer-sourced	0	PASS
AX-2025-021111	Tirzepatide	QST-2409-K5786	Nordanalyt	2024-Q4	98.84	6.45	89.5	Supplier-supplied	1	MARGINAL
AX-2025-021112	Tirzepatide	QST-2409-K5786	Janoshik	2024-Q4	98.02	5.78	98.6	Buyer-sourced	0	PASS
AX-2024-005327	Tirzepatide	QST-2409-K5786	Janoshik	2024-Q4	98.90	6.81	97.8	Supplier-supplied	0	PASS
AX-2024-005331	Tirzepatide	QST-2409-K5786	PeptideMeter	2024-Q4	97.53	5.57	—	Buyer-sourced	0	PASS
AX-2024-005330	Tirzepatide	QST-2409-K5786	Medutest	2024-Q4	97.89	6.25	91.3	Buyer-sourced	0	PASS
AX-2024-005332	Tirzepatide	QST-2409-K5786	Nordanalyt	2024-Q4	98.40	6.32	—	Buyer-sourced	0	PASS
AX-2024-005329	Tirzepatide	QST-2409-K5786	PeptideMeter	2024-Q4	98.10	6.65	—	Buyer-sourced	0	PASS